^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RB-340

    i
    Other names: RB-340
    Associations

    News

    Trials
    Company:
    Refuge Biotech, UT MD Anderson Cancer Center
    Drug class:
    PD1 inhibitor, HER2-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3years
    Contextual reprogramming of CAR-T cells for treatment of HER2 cancers. (PubMed, J Transl Med)
    As the first application of CRISPRi toward a clinically relevant product, RB-340-1 with the conditional, non-gene editing and reversible suppression promotes CAR-T cells resilience to checkpoint inhibition, and their persistence and effectiveness against HER2-expressing cancer xenografts.
    Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1)
    |
    HER-2 expression
    |
    RB-340